{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:26:40Z","timestamp":1794119200531,"version":"4.8.0"},"reference-count":221,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41584-018-0156-8","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T08:03:23Z","timestamp":1547798603000},"page":"137-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":401,"title":["Neuropsychiatric lupus: new mechanistic insights and future treatment directions"],"prefix":"10.1038","volume":"15","author":[{"given":"Noa","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel D.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3204-6068","authenticated-orcid":false,"given":"Chaim","family":"Putterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"156_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semarthrit.2010.08.001","volume":"41","author":"A Unterman","year":"2011","unstructured":"Unterman, A. et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin. Arthritis Rheum. 41, 1\u201311 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"156_CR2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.57.3.496","volume":"57","author":"H Ainiala","year":"2001","unstructured":"Ainiala, H., Loukkola, J., Peltola, J., Korpela, M. & Hietaharju, A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57, 496\u2013500 (2001).","journal-title":"Neurology"},{"key":"156_CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrrheum.2010.62","volume":"6","author":"GK Bertsias","year":"2010","unstructured":"Bertsias, G. K. & Boumpas, D. T. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat. Rev. Rheumatol. 6, 358\u2013367 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"156_CR4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semarthrit.2012.03.011","volume":"42","author":"AM Borowoy","year":"2012","unstructured":"Borowoy, A. M. et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 Faces of Lupus cohort. Semin. Arthritis Rheum. 42, 179\u2013185 (2012).","journal-title":"Semin. Arthritis Rheum."},{"key":"156_CR5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0961203311429116","volume":"21","author":"E Kozora","year":"2012","unstructured":"Kozora, E. et al. Immune function and brain abnormalities in patients with systemic lupus erythematosus without overt neuropsychiatric manifestations. Lupus 21, 402\u2013411 (2012).","journal-title":"Lupus"},{"key":"156_CR6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","volume":"42","author":"The American College of Rheumatology","year":"1999","unstructured":"The American College of Rheumatology. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 42, 599\u2013608 (1999).","journal-title":"Arthritis Rheum."},{"key":"156_CR7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/ard.2008.106351","volume":"69","author":"JG Hanly","year":"2010","unstructured":"Hanly, J. G. et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 529\u2013535 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR8","first-page":"766","volume":"28","author":"CC Mok","year":"2001","unstructured":"Mok, C. C., Lau, C. S. & Wong, R. W. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J. Rheumatol. 28, 766\u2013771 (2001).","journal-title":"J. Rheumatol."},{"key":"156_CR9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2015.10.003","volume":"15","author":"RC Ho","year":"2016","unstructured":"Ho, R. C. et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun. Rev. 15, 124\u2013138 (2016).","journal-title":"Autoimmun. Rev."},{"issue":"Suppl. 2","key":"156_CR10","doi-asserted-by":"crossref","first-page":"ii76","DOI":"10.1136\/annrheumdis-2012-202369","volume":"72","author":"GM Steup-Beekman","year":"2013","unstructured":"Steup-Beekman, G. M. et al. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause. Ann. Rheum. Dis. 72 (Suppl. 2), ii76\u2013ii79 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.62.9.859","volume":"62","author":"S Bujan","year":"2003","unstructured":"Bujan, S. et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann. Rheum. Dis. 62, 859\u2013865 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/ker310","volume":"51","author":"M Govoni","year":"2012","unstructured":"Govoni, M. et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 51, 157\u2013168 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"156_CR13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2016.06.013","volume":"74","author":"M Govoni","year":"2016","unstructured":"Govoni, M. et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J. Autoimmun. 74, 41\u201372 (2016).","journal-title":"J. Autoimmun."},{"key":"156_CR14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acr.23509","volume":"70","author":"JG Hanly","year":"2018","unstructured":"Hanly, J. G. et al. Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Care Res. 70, 1478\u20131487 (2018).","journal-title":"Arthritis Care Res."},{"key":"156_CR15","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/rheumatology\/keh384","volume":"43","author":"J Mikdashi","year":"2004","unstructured":"Mikdashi, J. & Handwerger, B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 43, 1555\u20131560 (2004).","journal-title":"Rheumatology (Oxford)"},{"key":"156_CR16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0889-857X(21)00209-X","volume":"19","author":"RL Brey","year":"1993","unstructured":"Brey, R. L., Gharavi, A. E. & Lockshin, M. D. Neurologic complications of antiphospholipid antibodies. Rheum. Dis. Clin. North Am. 19, 833\u2013850 (1993).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"156_CR17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0049-0172(79)80009-8","volume":"8","author":"SG Ellis","year":"1979","unstructured":"Ellis, S. G. & Verity, M. A. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955\u20131977. Semin. Arthritis Rheum. 8, 212\u2013221 (1979).","journal-title":"Semin. Arthritis Rheum."},{"key":"156_CR18","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3899\/jrheum.081133","volume":"36","author":"JG Hanly","year":"2009","unstructured":"Hanly, J. G. et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J. Rheumatol. 36, 1449\u20131459 (2009).","journal-title":"J. Rheumatol."},{"key":"156_CR19","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias, G. K. et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 69, 2074\u20132082 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/rheumatology\/kew341","volume":"56","author":"D Cohen","year":"2017","unstructured":"Cohen, D. et al. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford) 56, 77\u201386 (2017).","journal-title":"Rheumatology (Oxford)"},{"key":"156_CR21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.30157","volume":"63","author":"J Luyendijk","year":"2011","unstructured":"Luyendijk, J. et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum. 63, 722\u2013732 (2011).","journal-title":"Arthritis Rheum."},{"key":"156_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/art.40591","author":"JG Hanly","year":"2018","unstructured":"Hanly, J. G., Kozora, E., Beyea, S. & Birnbaum, J. Nervous system disease in systemic lupus erythematosus: current status and future directions. Arthritis Rheumatol. 71, 33\u201342 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"156_CR23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fmed.2018.00068","volume":"5","author":"A Bortoluzzi","year":"2018","unstructured":"Bortoluzzi, A., Scire, C. A. & Govoni, M. Attribution of neuropsychiatric manifestations to systemic lupus erythematosus. Front. Med. 5, 68 (2018).","journal-title":"Front. Med."},{"key":"156_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/art.22305","volume":"56","author":"JG Hanly","year":"2007","unstructured":"Hanly, J. G. et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 56, 265\u2013273 (2007).","journal-title":"Arthritis Rheum."},{"key":"156_CR25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.23566","volume":"59","author":"JG Hanly","year":"2008","unstructured":"Hanly, J. G. et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 59, 721\u2013729 (2008).","journal-title":"Arthritis Rheum."},{"key":"156_CR26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/rheumatology\/keu384","volume":"54","author":"A Bortoluzzi","year":"2015","unstructured":"Bortoluzzi, A. et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford) 54, 891\u2013898 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"156_CR27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/kex019","volume":"56","author":"C Magro-Checa","year":"2017","unstructured":"Magro-Checa, C. et al. Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. Rheumatology (Oxford) 56, 1676\u20131683 (2017).","journal-title":"Rheumatology (Oxford)"},{"key":"156_CR28","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/mp.2016.125","volume":"22","author":"E Castillo-Gomez","year":"2017","unstructured":"Castillo-Gomez, E. et al. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. Mol. Psychiatry 22, 1776\u20131784 (2017).","journal-title":"Mol. Psychiatry"},{"key":"156_CR29","doi-asserted-by":"crossref","first-page":"19854","DOI":"10.1073\/pnas.0608397104","volume":"103","author":"C Kowal","year":"2006","unstructured":"Kowal, C. et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl Acad. Sci. USA 103, 19854\u201319859 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"156_CR30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/art.38900","volume":"67","author":"M Bravo-Zehnder","year":"2015","unstructured":"Bravo-Zehnder, M. et al. Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol. 67, 204\u2013214 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"156_CR31","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.2174\/1381612821666150316115727","volume":"21","author":"Y Du","year":"2015","unstructured":"Du, Y., Sanam, S., Kate, K. & Mohan, C. Animal models of lupus and lupus nephritis. Curr. Pharm. Des. 21, 2320\u20132349 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"156_CR32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0021-9975(08)80122-3","volume":"102","author":"AB Kier","year":"1990","unstructured":"Kier, A. B. Clinical neurology and brain histopathology in NZB\/NZW F1 lupus mice. J. Comp. Pathol. 102, 165\u2013177 (1990).","journal-title":"J. Comp. Pathol."},{"key":"156_CR33","first-page":"443","volume":"34","author":"JW Leung","year":"2016","unstructured":"Leung, J. W., Lau, B. W., Chan, V. S., Lau, C. S. & So, K. F. Abnormal increase of neuronal precursor cells and exacerbated neuroinflammation in the corpus callosum in murine model of systemic lupus erythematosus. Restor. Neurol. Neurosci. 34, 443\u2013453 (2016).","journal-title":"Restor. Neurol. Neurosci."},{"key":"156_CR34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.brainresrev.2006.12.003","volume":"54","author":"DA Ballok","year":"2007","unstructured":"Ballok, D. A. Neuroimmunopathology in a murine model of neuropsychiatric lupus. Brain Res. Rev. 54, 67\u201379 (2007).","journal-title":"Brain Res. Rev."},{"key":"156_CR35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2172-15-23","volume":"15","author":"S Williams","year":"2014","unstructured":"Williams, S., Stafford, P. & Hoffman, S. A. Diagnosis and early detection of CNS-SLE in MRL\/lpr mice using peptide microarrays. BMC Immunol. 15, 23 (2014).","journal-title":"BMC Immunol."},{"key":"156_CR36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/eji.201343714","volume":"44","author":"JH Han","year":"2014","unstructured":"Han, J. H. et al. Expression of an anti-RNA autoantibody in a mouse model of SLE increases neutrophil and monocyte numbers as well as IFN-I expression. Eur. J. Immunol. 44, 215\u2013226 (2014).","journal-title":"Eur. J. Immunol."},{"key":"156_CR37","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3389\/fimmu.2017.01094","volume":"8","author":"G McDonald","year":"2017","unstructured":"McDonald, G. et al. Accelerated systemic autoimmunity in the absence of somatic hypermutation in 564Igi: a mouse model of systemic lupus with knocked-in heavy and light chain genes. Front. Immunol. 8, 1094 (2017).","journal-title":"Front. Immunol."},{"key":"156_CR38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature22821","volume":"546","author":"AR Bialas","year":"2017","unstructured":"Bialas, A. R. et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature 546, 539\u2013543 (2017).","journal-title":"Nature"},{"key":"156_CR39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbi.2018.03.009","volume":"70","author":"D Shi","year":"2018","unstructured":"Shi, D. et al. FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus. Brain Behav. Immun. 70, 293\u2013304 (2018).","journal-title":"Brain Behav. Immun."},{"key":"156_CR40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/0961203316688784","volume":"26","author":"LC Amorim de","year":"2017","unstructured":"de Amorim, L. C., Maia, F. M. & Rodrigues, C. E. Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment. Lupus 26, 529\u2013536 (2017).","journal-title":"Lupus"},{"key":"156_CR41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2014.11.001","volume":"14","author":"N Sarbu","year":"2015","unstructured":"Sarbu, N. et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun. Rev. 14, 153\u2013159 (2015).","journal-title":"Autoimmun. Rev."},{"key":"156_CR42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171558","volume":"12","author":"Z Merali","year":"2017","unstructured":"Merali, Z., Huang, K., Mikulis, D., Silver, F. & Kassner, A. Evolution of blood\u2013brain-barrier permeability after acute ischemic stroke. PLOS ONE 12, e0171558 (2017).","journal-title":"PLOS ONE"},{"key":"156_CR43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/jcbfm.2013.169","volume":"34","author":"M Kuntz","year":"2014","unstructured":"Kuntz, M. et al. Stroke-induced brain parenchymal injury drives blood\u2013brain barrier early leakage kinetics: a combined in vivo\/in vitro study. J. Cereb. Blood Flow Metab. 34, 95\u2013107 (2014).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"156_CR44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.neuron.2014.03.003","volume":"82","author":"D Knowland","year":"2014","unstructured":"Knowland, D. et al. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron 82, 603\u2013617 (2014).","journal-title":"Neuron"},{"key":"156_CR45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1042\/BST20140319","volume":"43","author":"KD Rochfort","year":"2015","unstructured":"Rochfort, K. D. & Cummins, P. M. The blood-brain barrier endothelium: a target for pro-inflammatory cytokines. Biochem. Soc. Trans. 43, 702\u2013706 (2015).","journal-title":"Biochem. Soc. Trans."},{"key":"156_CR46","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/01.STR.0000259709.16654.8f","volume":"38","author":"OB Dimitrijevic","year":"2007","unstructured":"Dimitrijevic, O. B., Stamatovic, S. M., Keep, R. F. & Andjelkovic, A. V. Absence of the chemokine receptor CCR2 protects against cerebral ischemia\/reperfusion injury in mice. Stroke 38, 1345\u20131353 (2007).","journal-title":"Stroke"},{"key":"156_CR47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9440(10)62273-0","volume":"166","author":"M Yepes","year":"2005","unstructured":"Yepes, M. et al. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am. J. Pathol. 166, 511\u2013520 (2005).","journal-title":"Am. J. Pathol."},{"key":"156_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00687674","volume":"76","author":"TS Salahuddin","year":"1988","unstructured":"Salahuddin, T. S., Kalimo, H., Johansson, B. B. & Olsson, Y. Observations on exudation of fibronectin, fibrinogen and albumin in the brain after carotid infusion of hyperosmolar solutions. An immunohistochemical study in the rat indicating long-lasting changes in the brain microenvironment and multifocal nerve cell injuries. Acta Neuropathol. 76, 1\u201310 (1988).","journal-title":"Acta Neuropathol."},{"key":"156_CR49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2015.03.005","volume":"60","author":"J Wen","year":"2015","unstructured":"Wen, J. et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL\/lpr mice. J. Autoimmun. 60, 40\u201350 (2015).","journal-title":"J. Autoimmun"},{"key":"156_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003347","volume":"3","author":"H Fragoso-Loyo","year":"2008","unstructured":"Fragoso-Loyo, H. et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLOS ONE 3, e3347 (2008).","journal-title":"PLOS ONE"},{"key":"156_CR51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1468-1331.2004.00976.x","volume":"12","author":"R Omdal","year":"2005","unstructured":"Omdal, R. et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12, 392\u2013398 (2005).","journal-title":"Eur. J. Neurol."},{"key":"156_CR52","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/ar4518","volume":"16","author":"S Hirohata","year":"2014","unstructured":"Hirohata, S., Arinuma, Y., Yanagida, T. & Yoshio, T. Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric\/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res. Ther. 16, R77 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"156_CR53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s13075-014-0450-z","volume":"16","author":"S Hirohata","year":"2014","unstructured":"Hirohata, S., Sakuma, Y., Yanagida, T. & Yoshio, T. Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus. Arthritis Res. Ther. 16, 450 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"156_CR54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM198707303170503","volume":"317","author":"E Bonfa","year":"1987","unstructured":"Bonfa, E. et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N. Engl. J. Med. 317, 265\u2013271 (1987).","journal-title":"N. Engl. J. Med."},{"key":"156_CR55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0002-9343(91)90506-S","volume":"90","author":"AB Schneebaum","year":"1991","unstructured":"Schneebaum, A. B. et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am. J. Med. 90, 54\u201362 (1991).","journal-title":"Am. J. Med."},{"key":"156_CR56","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/ard.51.9.1053","volume":"51","author":"Y Nojima","year":"1992","unstructured":"Nojima, Y. et al. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 51, 1053\u20131055 (1992).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR57","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/mp.2013.110","volume":"19","author":"C Hammer","year":"2014","unstructured":"Hammer, C. et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol. Psychiatry 19, 1143\u20131149 (2014).","journal-title":"Mol. Psychiatry"},{"key":"156_CR58","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1073\/pnas.0510055103","volume":"103","author":"PT Huerta","year":"2006","unstructured":"Huerta, P. T., Kowal, C., DeGiorgio, L. A., Volpe, B. T. & Diamond, B. Immunity and behavior: antibodies alter emotion. Proc. Natl Acad. Sci. USA 103, 678\u2013683 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"156_CR59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2004.07.011","volume":"21","author":"C Kowal","year":"2004","unstructured":"Kowal, C. et al. Cognition and immunity; antibody impairs memory. Immunity 21, 179\u2013188 (2004).","journal-title":"Immunity"},{"key":"156_CR60","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.22031","volume":"54","author":"L Lapteva","year":"2006","unstructured":"Lapteva, L. et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54, 2505\u20132514 (2006).","journal-title":"Arthritis Rheum."},{"key":"156_CR61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-12-804279-3.00002-2","volume":"146","author":"H Tumani","year":"2017","unstructured":"Tumani, H., Huss, A. & Bachhuber, F. The cerebrospinal fluid and barriers - anatomic and physiologic considerations. Handb. Clin. Neurol. 146, 21\u201332 (2017).","journal-title":"Handb Clin. Neurol."},{"key":"156_CR62","volume":"11","author":"L Yang","year":"2013","unstructured":"Yang, L. et al. Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer. J. Transl. Med. 11, 107 (2013).","journal-title":"J. Transl Med."},{"key":"156_CR63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015).","journal-title":"Nature"},{"key":"156_CR64","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000186504","volume":"61","author":"JF Baizabal-Carvallo","year":"2009","unstructured":"Baizabal-Carvallo, J. F., Delgadillo-Marquez, G., Estanol, B. & Garcia-Ramos, G. Clinical characteristics and outcomes of the meningitides in systemic lupus erythematosus. Eur. Neurol. 61, 143\u2013148 (2009).","journal-title":"Eur. Neurol."},{"key":"156_CR65","first-page":"OC05","volume":"11","author":"S Kakati","year":"2017","unstructured":"Kakati, S., Barman, B., Ahmed, S. U. & Hussain, M. Neurological manifestations in systemic lupus erythematosus: a single centre study from North East India. J. Clin. Diagn. Res. 11, OC05\u2013OC09 (2017).","journal-title":"J. Clin. Diagn. Res."},{"key":"156_CR66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/fcp.12349","volume":"32","author":"M Yelehe-Okouma","year":"2018","unstructured":"Yelehe-Okouma, M., Czmil-Garon, J., Pape, E., Petitpain, N. & Gillet, P. Drug-induced aseptic meningitis: a mini-review. Fund. Clin. Pharmacol. 32, 252\u2013260 (2018).","journal-title":"Fund. Clin. Pharmacol."},{"key":"156_CR67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11481-016-9705-6","volume":"12","author":"KEB Veen van","year":"2017","unstructured":"van Veen, K. E. B., Brouwer, M. C., van der Ende, A. & van de Beek, D. Bacterial meningitis in patients using immunosuppressive medication: a population-based prospective nationwide study. J. Neuroimmune Pharmacol. 12, 213\u2013218 (2017).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"156_CR68","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ni.1716","volume":"10","author":"A Reboldi","year":"2009","unstructured":"Reboldi, A. et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10, 514\u2013523 (2009).","journal-title":"Nat. Immunol."},{"key":"156_CR69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.1252945","volume":"346","author":"K Baruch","year":"2014","unstructured":"Baruch, K. et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89\u201393 (2014).","journal-title":"Science"},{"key":"156_CR70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7326\/0003-4819-76-1-65","volume":"76","author":"CJ Atkins","year":"1972","unstructured":"Atkins, C. J., Kondon, J. J., Quismorio, F. P. & Friou, G. J. The choroid plexus in systemic lupus erythematosus. Ann. Intern. Med. 76, 65\u201372 (1972).","journal-title":"Ann. Intern. Med."},{"key":"156_CR71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-3476(74)80125-3","volume":"85","author":"JH Sher","year":"1974","unstructured":"Sher, J. H. & Pertschuk, L. P. Immunoglobulin G deposits in the choroid plexus of a child with systemic lupus erythematosus. J. Pediatr. 85, 385\u2013387 (1974).","journal-title":"J. Pediatr."},{"key":"156_CR72","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0022-3476(75)80831-6","volume":"87","author":"ME Gershwin","year":"1975","unstructured":"Gershwin, M. E., Hyman, L. R. & Steinberg, A. D. The choroid plexus in CNS involvement of systemic lupus erythematosus. J. Pediatr. 87, 588\u2013590 (1975).","journal-title":"J. Pediatr."},{"key":"156_CR73","first-page":"645","volume":"7","author":"RS Boyer","year":"1980","unstructured":"Boyer, R. S., Sun, N. C., Verity, A., Nies, K. M. & Louie, J. S. Immunoperoxidase staining of the choroid plexus in systemic lupus erythematosus. J. Rheumatol. 7, 645\u2013650 (1980).","journal-title":"J. Rheumatol."},{"key":"156_CR74","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.3899\/jrheum.090027","volume":"36","author":"E Amaro Jr","year":"2009","unstructured":"Amaro, E. Jr & Scheinberg, M. Onset of cognitive dysfunction in systemic lupus erythematosus and selective involvement of the choroid plexus. J. Rheumatol. 36, 2554\u20132555 (2009).","journal-title":"J. Rheumatol."},{"key":"156_CR75","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4049\/jimmunol.194.Supp.114.1","volume":"194","author":"A Stock","year":"2015","unstructured":"Stock, A., Wen, J., Doerner, J. & Putterman, C. Neuropsychiatric lupus occurs independently of systemic autoimmunity. J. Immunol. 194, 2 (2015).","journal-title":"J. Immunol."},{"key":"156_CR76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2249.2006.03056.x","volume":"144","author":"WG James","year":"2006","unstructured":"James, W. G., Hutchinson, P., Bullard, D. C. & Hickey, M. J. Cerebral leucocyte infiltration in lupus-prone MRL\/MpJ-fas lpr mice \u2014 roles of intercellular adhesion molecule-1 and P-selectin. Clin. Exp. Immunol. 144, 299\u2013308 (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"156_CR77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jneuroim.2006.06.023","volume":"179","author":"X Ma","year":"2006","unstructured":"Ma, X., Foster, J. & Sakic, B. Distribution and prevalence of leukocyte phenotypes in brains of lupus-prone mice. J. Neuroimmunol. 179, 26\u201336 (2006).","journal-title":"J. Neuroimmunol."},{"key":"156_CR78","first-page":"2199","volume":"33","author":"DA Ballok","year":"2006","unstructured":"Ballok, D. A., Ma, X., Denburg, J. A., Arsenault, L. & Sakic, B. Ibuprofen fails to prevent brain pathology in a model of neuropsychiatric lupus. J. Rheumatol. 33, 2199\u20132213 (2006).","journal-title":"J. Rheumatol."},{"key":"156_CR79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2018.03.001","volume":"91","author":"S Gelb","year":"2018","unstructured":"Gelb, S., Stock, A. D., Anzi, S., Putterman, C. & Ben-Zvi, A. Mechanisms of neuropsychiatric lupus: the relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J. Autoimmun. 91, 34\u201344 (2018).","journal-title":"J. Autoimmun."},{"key":"156_CR80","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.autrev.2017.04.008","volume":"16","author":"AD Stock","year":"2017","unstructured":"Stock, A. D., Gelb, S., Pasternak, O., Ben-Zvi, A. & Putterman, C. The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmun. Rev. 16, 612\u2013619 (2017).","journal-title":"Autoimmun. Rev."},{"key":"156_CR81","doi-asserted-by":"crossref","first-page":"18005","DOI":"10.1038\/nrdp.2018.5","volume":"4","author":"K Schreiber","year":"2018","unstructured":"Schreiber, K. et al. Antiphospholipid syndrome. Nat. Rev. Dis. Primers 4, 18005 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"156_CR82","volume":"10","author":"C Gao","year":"2015","unstructured":"Gao, C. et al. Thrombotic role of blood and endothelial cells in uremia through phosphatidylserine exposure and microparticle release. PLOS ONE 10, e0142835b (2015).","journal-title":"PLOS ONE"},{"key":"156_CR83","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","volume":"368","author":"B Giannakopoulos","year":"2013","unstructured":"Giannakopoulos, B. & Krilis, S. A. The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 368, 1033\u20131044 (2013).","journal-title":"N. Engl. J. Med."},{"key":"156_CR84","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0961203310382429","volume":"20","author":"CB Narshi","year":"2011","unstructured":"Narshi, C. B., Giles, I. P. & Rahman, A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus 20, 5\u201313 (2011).","journal-title":"Lupus"},{"key":"156_CR85","doi-asserted-by":"crossref","first-page":"I19","DOI":"10.1161\/01.STR.23.12.1748","volume":"23","author":"SJ Kittner","year":"1992","unstructured":"Kittner, S. J. & Gorelick, P. B. Antiphospholipid antibodies and stroke: an epidemiological perspective. Stroke 23, I19\u201322 (1992).","journal-title":"Stroke"},{"key":"156_CR86","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.2007.077594","volume":"67","author":"RM Andrade","year":"2008","unstructured":"Andrade, R. M. et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann. Rheum. Dis. 67, 829\u2013834 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR87","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1212\/01.WNL.0000144178.32208.4F","volume":"63","author":"S Appenzeller","year":"2004","unstructured":"Appenzeller, S., Cendes, F. & Costallat, L. T. Epileptic seizures in systemic lupus erythematosus. Neurology 63, 1808\u20131812 (2004).","journal-title":"Neurology"},{"key":"156_CR88","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000149640.78684.EA","volume":"64","author":"EY McLaurin","year":"2005","unstructured":"McLaurin, E. Y., Holliday, S. L., Williams, P. & Brey, R. L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64, 297\u2013303 (2005).","journal-title":"Neurology"},{"key":"156_CR89","first-page":"622","volume":"32","author":"MY Mok","year":"2005","unstructured":"Mok, M. Y. et al. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 32, 622\u2013628 (2005).","journal-title":"J. Rheumatol."},{"key":"156_CR90","first-page":"985","volume":"30","author":"G Sanna","year":"2003","unstructured":"Sanna, G. et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 30, 985\u2013992 (2003).","journal-title":"J. Rheumatol."},{"key":"156_CR91","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/art.23098","volume":"57","author":"P Tomietto","year":"2007","unstructured":"Tomietto, P. et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 57, 1461\u20131472 (2007).","journal-title":"Arthritis Rheum."},{"key":"156_CR92","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2014.04.003","volume":"272","author":"A Katzav","year":"2014","unstructured":"Katzav, A. et al. Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J. Neuroimmunol. 272, 10\u201315 (2014).","journal-title":"J. Neuroimmunol."},{"key":"156_CR93","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s11064-008-9902-7","volume":"34","author":"OZ Chi","year":"2009","unstructured":"Chi, O. Z., Hunter, C., Liu, X. & Weiss, H. R. Effects of exogenous excitatory amino acid neurotransmitters on blood-brain barrier disruption in focal cerebral ischemia. Neurochem. Res. 34, 1249\u20131254 (2009).","journal-title":"Neurochem. Res."},{"key":"156_CR94","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2249.2006.03102.x","volume":"145","author":"H Du","year":"2006","unstructured":"Du, H., Chen, M., Zhang, Y., Zhao, M. H. & Wang, H. Y. Cross-reaction of anti-DNA autoantibodies with membrane proteins of human glomerular mesangial cells in sera from patients with lupus nephritis. Clin. Exp. Immunol. 145, 21\u201327 (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"156_CR95","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/art.20862","volume":"52","author":"Z Zhao","year":"2005","unstructured":"Zhao, Z. et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum. 52, 522\u2013530 (2005).","journal-title":"Arthritis Rheum."},{"key":"156_CR96","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/nm1101-1189","volume":"7","author":"LA DeGiorgio","year":"2001","unstructured":"DeGiorgio, L. A. et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189\u20131193 (2001).","journal-title":"Nat. Med."},{"key":"156_CR97","doi-asserted-by":"crossref","first-page":"18569","DOI":"10.1073\/pnas.1006980107","volume":"107","author":"TW Faust","year":"2010","unstructured":"Faust, T. W. et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl Acad. Sci. USA 107, 18569\u201318574 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"156_CR98","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2008.11.009","volume":"207","author":"HX Gao","year":"2009","unstructured":"Gao, H. X. et al. Depression is an early disease manifestation in lupus-prone MRL\/lpr mice. J. Neuroimmunol. 207, 45\u201356 (2009).","journal-title":"J. Neuroimmunol."},{"key":"156_CR99","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/art.23399","volume":"58","author":"Y Arinuma","year":"2008","unstructured":"Arinuma, Y., Yanagida, T. & Hirohata, S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 58, 1130\u20131135 (2008).","journal-title":"Arthritis Rheum."},{"key":"156_CR100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2010.04.016","volume":"295","author":"E Kozora","year":"2010","unstructured":"Kozora, E. et al. Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. J. Neurol. Sci. 295, 87\u201391 (2010).","journal-title":"J. Neurol. Sci."},{"key":"156_CR101","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3899\/jrheum.091366","volume":"37","author":"M Petri","year":"2010","unstructured":"Petri, M. et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J. Rheumatol. 37, 2032\u20132038 (2010).","journal-title":"J. Rheumatol."},{"key":"156_CR102","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.it.2015.09.008","volume":"36","author":"L Brimberg","year":"2015","unstructured":"Brimberg, L. et al. Antibodies as mediators of brain pathology. Trends Immunol. 36, 709\u2013724 (2015).","journal-title":"Trends Immunol."},{"key":"156_CR103","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/ard.2004.029280","volume":"64","author":"ES Husebye","year":"2005","unstructured":"Husebye, E. S. et al. Autoantibodies to a NR2A peptide of the glutamate\/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64, 1210\u20131213 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR104","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1084\/jem.20180776","volume":"215","author":"J Nestor","year":"2018","unstructured":"Nestor, J. et al. Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors. J. Exp. Med. 215, 2554\u20132566 (2018).","journal-title":"J. Exp. Med."},{"key":"156_CR105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1191\/0961203305lu2150rr","volume":"14","author":"T Eber","year":"2005","unstructured":"Eber, T., Chapman, J. & Shoenfeld, Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 14, 571\u2013575 (2005).","journal-title":"Lupus"},{"key":"156_CR106","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.59.2.99","volume":"59","author":"AG Tzioufas","year":"2000","unstructured":"Tzioufas, A. G. et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann. Rheum. Dis. 59, 99\u2013104 (2000).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clim.2008.10.010","volume":"130","author":"SD Moscavitch","year":"2009","unstructured":"Moscavitch, S. D., Szyper-Kravitz, M. & Shoenfeld, Y. Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system interrelationship. Clin. Immunol. 130, 235\u2013243 (2009).","journal-title":"Clin. Immunol."},{"key":"156_CR108","first-page":"1681","volume":"22","author":"T Yoshio","year":"1995","unstructured":"Yoshio, T. et al. Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J. Rheumatol. 22, 1681\u20131687 (1995).","journal-title":"J. Rheumatol."},{"key":"156_CR109","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/art.22419","volume":"56","author":"A Katzav","year":"2007","unstructured":"Katzav, A. et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 56, 938\u2013948 (2007).","journal-title":"Arthritis Rheum."},{"key":"156_CR110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaut.2008.09.002","volume":"31","author":"A Katzav","year":"2008","unstructured":"Katzav, A. et al. Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J. Autoimmun. 31, 393\u2013398 (2008).","journal-title":"J. Autoimmun."},{"key":"156_CR111","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12016-012-8343-x","volume":"45","author":"C Perricone","year":"2013","unstructured":"Perricone, C. et al. Smell and autoimmunity: a comprehensive review. Clin. Rev. Allergy Immunol. 45, 87\u201396 (2013).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"156_CR112","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neubiorev.2005.03.010","volume":"29","author":"C Song","year":"2005","unstructured":"Song, C. & Leonard, B. E. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 29, 627\u2013647 (2005).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"156_CR113","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.162.2.459","volume":"162","author":"KB Elkon","year":"1985","unstructured":"Elkon, K. B., Parnassa, A. P. & Foster, C. L. Lupus autoantibodies target ribosomal P proteins. J. Exp. Med. 162, 459\u2013471 (1985).","journal-title":"J. Exp. Med."},{"key":"156_CR114","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/art.39081","volume":"67","author":"F Segovia-Miranda","year":"2015","unstructured":"Segovia-Miranda, F. et al. Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model. Arthritis Rheumatol. 67, 1598\u20131610 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"156_CR115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/s10165-010-0354-y","volume":"21","author":"T Nagai","year":"2011","unstructured":"Nagai, T., Yanagida, T. & Hirohata, S. Anti-ribosomal P protein antibody induces Th1 responses by enhancing the production of IL-12 in activated monocytes. Mod. Rheumatol. 21, 57\u201362 (2011).","journal-title":"Mod. Rheumatol."},{"key":"156_CR116","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473\u2013477 (2005).","journal-title":"J. Exp. Med."},{"key":"156_CR117","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1468-1331.2011.03479.x","volume":"19","author":"A Dellavance","year":"2012","unstructured":"Dellavance, A. et al. Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases. Eur. J. Neurol. 19, 248\u2013252 (2012).","journal-title":"Eur. J. Neurol."},{"key":"156_CR118","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bpa.12085","volume":"23","author":"AS Verkman","year":"2013","unstructured":"Verkman, A. S., Phuan, P. W., Asavapanumas, N. & Tradtrantip, L. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol. 23, 684\u2013695 (2013).","journal-title":"Brain Pathol."},{"key":"156_CR119","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","volume":"65","author":"P Waters","year":"2008","unstructured":"Waters, P. et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch. Neurol. 65, 913\u2013919 (2008).","journal-title":"Arch. Neurol."},{"key":"156_CR120","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters, P. J. et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78, 665\u2013671 (2012).","journal-title":"Neurology"},{"key":"156_CR121","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.40356","volume":"70","author":"S Mader","year":"2018","unstructured":"Mader, S. et al. Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets? Arthritis Rheumatol. 70, 277\u2013286 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"156_CR122","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl, M. et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66, 630\u2013643 (2009).","journal-title":"Ann. Neurol."},{"key":"156_CR123","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai9111","volume":"9","author":"F Shimizu","year":"2017","unstructured":"Shimizu, F. et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci. Transl. Med. 9, eaai9111 (2017).","journal-title":"Sci. Transl Med."},{"key":"156_CR124","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jneuroim.2015.10.007","volume":"289","author":"H Alexopoulos","year":"2015","unstructured":"Alexopoulos, H. et al. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. J. Neuroimmunol. 289, 8\u201311 (2015).","journal-title":"J. Neuroimmunol."},{"key":"156_CR125","doi-asserted-by":"crossref","first-page":"R366","DOI":"10.1186\/ar1198","volume":"6","author":"F Conti","year":"2004","unstructured":"Conti, F. et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res. Ther. 6, R366\u2013R372 (2004).","journal-title":"Arthritis Res. Ther."},{"key":"156_CR126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002960000060","volume":"20","author":"J Song","year":"2000","unstructured":"Song, J., Park, Y. B., Lee, W. K., Lee, K. H. & Lee, S. K. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol. Int. 20, 1\u20137 (2000).","journal-title":"Rheumatol. Int."},{"key":"156_CR127","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.21797","volume":"54","author":"H Nara","year":"2006","unstructured":"Nara, H., Okamoto, H., Minota, S. & Yoshio, T. Mouse monoclonal anti-human thrombomodulin antibodies bind to and activate endothelial cells through NF-\u03baB activation in vitro. Arthritis Rheum. 54, 1629\u20131637 (2006).","journal-title":"Arthritis Rheum."},{"key":"156_CR128","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/39.10.1114","volume":"39","author":"G Frampton","year":"2000","unstructured":"Frampton, G. et al. Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen. Rheumatology (Oxford) 39, 1114\u20131120 (2000).","journal-title":"Rheumatology (Oxford)"},{"key":"156_CR129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/art.20156","volume":"50","author":"RC Williams Jr.","year":"2004","unstructured":"Williams, R. C. Jr., Sugiura, K. & Tan, E. M. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 50, 1239\u20131247 (2004).","journal-title":"Arthritis Rheum."},{"key":"156_CR130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/14397595.2015.1123345","volume":"26","author":"Y Yamada","year":"2016","unstructured":"Yamada, Y. et al. Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus. Mod. Rheum. 26, 562\u2013568 (2016).","journal-title":"Mod. Rheum."},{"key":"156_CR131","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ygeno.2004.03.010","volume":"84","author":"T Matsui","year":"2004","unstructured":"Matsui, T. et al. Identification of novel keratinocyte-secreted peptides dermokine-alpha\/-beta and a new stratified epithelium-secreted protein gene complex on human chromosome 19q13.1. Genomics 84, 384\u2013397 (2004).","journal-title":"Genomics"},{"key":"156_CR132","doi-asserted-by":"crossref","first-page":"45195","DOI":"10.1074\/jbc.M205380200","volume":"277","author":"GT Park","year":"2002","unstructured":"Park, G. T., Lim, S. E., Jang, S. I. & Morasso, M. I. Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor. J. Biol. Chem. 277, 45195\u201345202 (2002).","journal-title":"J. Biol. Chem."},{"key":"156_CR133","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.clim.2017.11.006","volume":"193","author":"K Ichinose","year":"2018","unstructured":"Ichinose, K. et al. Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus. Clin. Immunol. 193, 123\u2013130 (2018).","journal-title":"Clin. Immunol."},{"key":"156_CR134","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4049\/jimmunol.170.1.520","volume":"170","author":"WG James","year":"2003","unstructured":"James, W. G., Bullard, D. C. & Hickey, M. J. Critical role of the alpha 4 integrin\/VCAM-1 pathway in cerebral leukocyte trafficking in lupus-prone MRL\/fas (lpr) mice. J. Immunol. 170, 520\u2013527 (2003).","journal-title":"J. Immunol."},{"key":"156_CR135","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","volume":"181","author":"JC Crispin","year":"2008","unstructured":"Crispin, J. C. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181, 8761\u20138766 (2008).","journal-title":"J. Immunol."},{"key":"156_CR136","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4049\/jimmunol.143.1.103","volume":"143","author":"S Shivakumar","year":"1989","unstructured":"Shivakumar, S., Tsokos, G. C. & Datta, S. K. T cell receptor alpha\/beta expressing double-negative (CD4\u2013\/CD8\u2013) and CD4+T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 143, 103\u2013112 (1989).","journal-title":"J. Immunol."},{"key":"156_CR137","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fimmu.2018.00487","volume":"9","author":"S Jain","year":"2018","unstructured":"Jain, S., Stock, A., Macian, F. & Putterman, C. A distinct T follicular helper cell subset infiltrates the brain in murine neuropsychiatric lupus. Front. Immunol. 9, 487 (2018).","journal-title":"Front. Immunol."},{"key":"156_CR138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molmed.2009.12.005","volume":"16","author":"JC Crispin","year":"2010","unstructured":"Crispin, J. C. et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 16, 47\u201357 (2010).","journal-title":"Trends Mol. Med."},{"key":"156_CR139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2014.11.007","volume":"57","author":"SA Chalmers","year":"2015","unstructured":"Chalmers, S. A. et al. Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. J. Autoimmun. 57, 42\u201352 (2015).","journal-title":"J. Autoimmun."},{"key":"156_CR140","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.4049\/jimmunol.181.10.7367","volume":"181","author":"J Menke","year":"2008","unstructured":"Menke, J. et al. Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice. J. Immunol. 181, 7367\u20137379 (2008).","journal-title":"J. Immunol."},{"key":"156_CR141","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.biopsych.2009.12.008","volume":"67","author":"R Crupi","year":"2010","unstructured":"Crupi, R. et al. Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B cell activating factor transgenic mice. Biol. Psychiatry 67, 558\u2013566 (2010).","journal-title":"Biol. Psychiatry"},{"key":"156_CR142","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbi.2008.01.013","volume":"22","author":"TK Mondal","year":"2008","unstructured":"Mondal, T. K., Saha, S. K., Miller, V. M., Seegal, R. F. & Lawrence, D. A. Autoantibody-mediated neuroinflammation: pathogenesis of neuropsychiatric systemic lupus erythematosus in the NZM88 murine model. Brain Behav. Immun. 22, 949\u2013959 (2008).","journal-title":"Brain Behav. Immun."},{"key":"156_CR143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-017-1500-0","volume":"20","author":"SA Chalmers","year":"2018","unstructured":"Chalmers, S. A. et al. Highly selective inhibition of Bruton\u2019s tyrosine kinase attenuates skin and brain disease in murine lupus. Arthritis Res. Ther. 20, 10 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"156_CR144","first-page":"732","volume":"19","author":"JG Hanly","year":"1992","unstructured":"Hanly, J. G., Walsh, N. M. & Sangalang, V. Brain pathology in systemic lupus erythematosus. J. Rheumatol. 19, 732\u2013741 (1992).","journal-title":"J. Rheumatol."},{"key":"156_CR145","first-page":"387","volume":"28","author":"T Duprez","year":"2001","unstructured":"Duprez, T., Nzeusseu, A., Peeters, A. & Houssiau, F. A. Selective involvement of the choroid plexus on cerebral magnetic resonance images: a new radiological sign in patients with systemic lupus erythematosus with neurological symptoms. J. Rheumatol. 28, 387\u2013391 (2001).","journal-title":"J. Rheumatol."},{"key":"156_CR146","doi-asserted-by":"crossref","first-page":"15150","DOI":"10.3390\/ijms160715150","volume":"16","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Behavioral deficits are accompanied by immunological and neurochemical changes in a mouse model for neuropsychiatric lupus (NP-SLE). Int. J. Mol. Sci. 16, 15150\u201315171 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"156_CR147","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/art.1780350410","volume":"35","author":"S Shiozawa","year":"1992","unstructured":"Shiozawa, S., Kuroki, Y., Kim, M., Hirohata, S. & Ogino, T. Interferon-alpha in lupus psychosis. Arthritis Rheum. 35, 417\u2013422 (1992).","journal-title":"Arthritis Rheum."},{"key":"156_CR148","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/rheumatology\/ket294","volume":"52","author":"H Fragoso-Loyo","year":"2013","unstructured":"Fragoso-Loyo, H., Atisha-Fregoso, Y., Llorente, L. & Sanchez-Guerrero, J. Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 52, 2218\u20132222 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"156_CR149","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4049\/jimmunol.182.2.1192","volume":"182","author":"DM Santer","year":"2009","unstructured":"Santer, D. M., Yoshio, T., Minota, S., Moller, T. & Elkon, K. B. Potent induction of IFN-\u03b1 and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J. Immunol. 182, 1192\u20131201 (2009).","journal-title":"J. Immunol."},{"key":"156_CR150","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e32832e089e","volume":"21","author":"L Ronnblom","year":"2009","unstructured":"Ronnblom, L., Alm, G. V. & Eloranta, M. L. Type I interferon and lupus. Curr. Opin. Rheumatol. 21, 471\u2013477 (2009).","journal-title":"Curr. Opin. Rheumatol."},{"key":"156_CR151","doi-asserted-by":"crossref","first-page":"273907","DOI":"10.1155\/2011\/273907","volume":"2011","author":"TP Karageorgas","year":"2011","unstructured":"Karageorgas, T. P., Tseronis, D. D. & Mavragani, C. P. Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes. J. Biomed. Biotechnol. 2011, 273907 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"156_CR152","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/0961203316629556","volume":"25","author":"T Yoshio","year":"2016","unstructured":"Yoshio, T. et al. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus 25, 997\u20131003 (2016).","journal-title":"Lupus"},{"key":"156_CR153","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.110983","volume":"39","author":"H Fragoso-Loyo","year":"2012","unstructured":"Fragoso-Loyo, H., Atisha-Fregoso, Y., Nunez-Alvarez, C. A., Llorente, L. & Sanchez-Guerrero, J. Utility of interferon-alpha as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus. J. Rheumatol 39, 504\u2013509 (2012).","journal-title":"J. Rheumatol"},{"key":"156_CR154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.1390070","volume":"192","author":"J Wen","year":"2014","unstructured":"Wen, J. et al. Inhibiting TWEAK (TNF-like weak inducer of apoptosis) signaling ameliorates blood brain barrier integrity and neuronal damage in neuropsychiatric lupus prone MRL\/lpr mice. J. Immunol. 192, 1 (2014).","journal-title":"J. Immunol."},{"key":"156_CR155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.03.002","volume":"43","author":"J Wen","year":"2013","unstructured":"Wen, J. et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK\/Fn14 pathway. J. Autoimmun. 43, 44\u201354 (2013).","journal-title":"J. Autoimmun."},{"key":"156_CR156","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/0961203315610206","volume":"25","author":"H Fragoso-Loyo","year":"2016","unstructured":"Fragoso-Loyo, H., Atisha-Fregoso, Y., Nunez-Alvarez, C. A. & Llorente, L. Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erythematosus. Lupus 25, 364\u2013369 (2016).","journal-title":"Lupus"},{"key":"156_CR157","first-page":"2010","volume":"34","author":"Y Katsumata","year":"2007","unstructured":"Katsumata, Y. et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J. Rheumatol. 34, 2010\u20132017 (2007).","journal-title":"J. Rheumatol."},{"key":"156_CR158","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s10067-009-1226-8","volume":"28","author":"S Hirohata","year":"2009","unstructured":"Hirohata, S. et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin. Rheumatol. 28, 1319\u20131323 (2009).","journal-title":"Clin. Rheumatol."},{"key":"156_CR159","volume":"12","author":"T Asano","year":"2017","unstructured":"Asano, T. et al. Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus. PLOS ONE 12, e0186414 (2017).","journal-title":"PLOS ONE"},{"key":"156_CR160","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clim.2015.01.010","volume":"157","author":"K Ichinose","year":"2015","unstructured":"Ichinose, K. et al. Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. Clin. Immunol. 157, 114\u2013120 (2015).","journal-title":"Clin. Immunol."},{"key":"156_CR161","first-page":"16658","volume":"8","author":"JB Wang","year":"2015","unstructured":"Wang, J. B. et al. Role of IL-1\u03b2, IL-6, IL-8 and IFN-\u03b3 in pathogenesis of central nervous system neuropsychiatric systemic lupus erythematous. Int. J. Clin. Exp. Med. 8, 16658\u201316663 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"156_CR162","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-pathol-051217-111018","volume":"13","author":"BA Plog","year":"2018","unstructured":"Plog, B. A. & Nedergaard, M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu. Rev. Pathol. 13, 379\u2013394 (2018).","journal-title":"Annu. Rev. Pathol."},{"key":"156_CR163","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s40674-014-0009-9","volume":"1","author":"GS Gilkeson","year":"2015","unstructured":"Gilkeson, G. S. Complement-targeted therapies in lupus. Curr. Treatm Opt. Rheumatol. 1, 10\u201318 (2015).","journal-title":"Curr. Treatm Opt. Rheumatol."},{"key":"156_CR164","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.4049\/jimmunol.175.12.8312","volume":"175","author":"JJ Alexander","year":"2005","unstructured":"Alexander, J. J., Jacob, A., Bao, L., Macdonald, R. L. & Quigg, R. J. Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis. J. Immunol. 175, 8312\u20138319 (2005).","journal-title":"J. Immunol."},{"key":"156_CR165","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1212\/WNL.40.10.1593","volume":"40","author":"PJ Jongen","year":"1990","unstructured":"Jongen, P. J., Boerbooms, A. M., Lamers, K. J., Raes, B. C. & Vierwinden, G. Diffuse CNS involvement in systemic lupus erythematosus: intrathecal synthesis of the 4th component of complement. Neurology 40, 1593\u20131596 (1990).","journal-title":"Neurology"},{"key":"156_CR166","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1600-0404.2000.101002116.x","volume":"101","author":"PJ Jongen","year":"2000","unstructured":"Jongen, P. J. et al. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol. Scand. 101, 116\u2013121 (2000).","journal-title":"Acta Neurol. Scand."},{"key":"156_CR167","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/14397595.2016.1193965","volume":"27","author":"Y Sakuma","year":"2017","unstructured":"Sakuma, Y., Nagai, T., Yoshio, T. & Hirohata, S. Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus. Mod. Rheumatol. 27, 292\u2013297 (2017).","journal-title":"Mod. Rheumatol."},{"key":"156_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.03.001","author":"C Dobrowolski","year":"2018","unstructured":"Dobrowolski, C. & Erkan, D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin. Immunol. https:\/\/doi.org\/10.1016\/j.clim.2018.03.001 (2018).","journal-title":"Clin. Immunol."},{"key":"156_CR169","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000143","volume":"93","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler, A. et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine 93, e143 (2014).","journal-title":"Medicine"},{"key":"156_CR170","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","volume":"64","author":"I Shapira","year":"2012","unstructured":"Shapira, I., Andrade, D., Allen, S. L. & Salmon, J. E. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 64, 2719\u20132723 (2012).","journal-title":"Arthritis Rheum."},{"key":"156_CR171","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13543784.2018.1443077","volume":"27","author":"F Paul","year":"2018","unstructured":"Paul, F., Murphy, O., Pardo, S. & Levy, M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin. Investig. Drugs 27, 265\u2013271 (2018).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"156_CR172","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jneuroim.2017.06.008","volume":"311","author":"HW Lei","year":"2017","unstructured":"Lei, H. W. et al. Neuropsychiatric involvement in lupus is associated with the Nogo-a\/NgR1 pathway. J. Neuroimmunol. 311, 22\u201328 (2017).","journal-title":"J. Neuroimmunol."},{"key":"156_CR173","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-018-0023-4","volume":"556","author":"AC Wendeln","year":"2018","unstructured":"Wendeln, A. C. et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature 556, 332\u2013338 (2018).","journal-title":"Nature"},{"key":"156_CR174","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04648-0","volume":"9","author":"A Schrepf","year":"2018","unstructured":"Schrepf, A. et al. A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis. Nat. Commun. 9, 2243 (2018).","journal-title":"Nat. Commun."},{"key":"156_CR175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-018-1516-0","volume":"20","author":"J Nystedt","year":"2018","unstructured":"Nystedt, J. et al. Altered white matter microstructure in lupus patients: a diffusion tensor imaging study. Arthritis Res. Ther. 20, 21 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"156_CR176","doi-asserted-by":"crossref","first-page":"745647","DOI":"10.1155\/2015\/745647","volume":"2015","author":"F Ceccarelli","year":"2015","unstructured":"Ceccarelli, F. et al. Genetic factors in systemic lupus erythematosus: contribution to disease phenotype. J. Immunol. Res. 2015, 745647 (2015).","journal-title":"J. Immunol. Res."},{"key":"156_CR177","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1136\/ard.2009.114157","volume":"69","author":"B Vries de","year":"2010","unstructured":"de Vries, B. et al. TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Ann. Rheum. Dis. 69, 1886\u20131887 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR178","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/gene.2010.73","volume":"12","author":"B Namjou","year":"2011","unstructured":"Namjou, B. et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12, 270\u2013279 (2011).","journal-title":"Genes Immun."},{"key":"156_CR179","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/annrheumdis-2012-201760","volume":"72","author":"E Lundstrom","year":"2013","unstructured":"Lundstrom, E. et al. HLA-DRB1*04\/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann. Rheum. Dis. 72, 1018\u20131025 (2013).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 2","key":"156_CR180","doi-asserted-by":"crossref","first-page":"ii56","DOI":"10.1136\/annrheumdis-2012-202351","volume":"72","author":"OJ Rullo","year":"2013","unstructured":"Rullo, O. J. & Tsao, B. P. Recent insights into the genetic basis of systemic lupus erythematosus. Ann. Rheum. Dis. 72 (Suppl. 2), ii56\u2013ii61 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR181","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/jhg.2011.49","volume":"56","author":"M Koga","year":"2011","unstructured":"Koga, M. et al. Cumulative association of eight susceptibility genes with systemic lupus erythematosus in a Japanese female population. J. Hum. Gen. 56, 503\u2013507 (2011).","journal-title":"J. Hum. Gen."},{"key":"156_CR182","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2004.025528","volume":"64","author":"L Barile-Fabris","year":"2005","unstructured":"Barile-Fabris, L. et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 620\u2013625 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR183","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9343(03)00135-9","volume":"115","author":"CC Mok","year":"2003","unstructured":"Mok, C. C., Lau, C. S. & Wong, R. W. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am. J. Med. 115, 59\u201362 (2003).","journal-title":"Am. J. Med."},{"key":"156_CR184","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"M Tokunaga","year":"2007","unstructured":"Tokunaga, M. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66, 470\u2013475 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR185","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","volume":"83","author":"RC Dale","year":"2014","unstructured":"Dale, R. C. et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 83, 142\u2013150 (2014).","journal-title":"Neurology"},{"key":"156_CR186","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob, A. et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65, 1443\u20131448 (2008).","journal-title":"Arch. Neurol."},{"key":"156_CR187","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","volume":"28","author":"MR Pranzatelli","year":"2006","unstructured":"Pranzatelli, M. R. et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J. Pediatr. Hematol. Oncol. 28, 585\u2013593 (2006).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"156_CR188","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer, M. J. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 12, 157\u2013165 (2013).","journal-title":"Lancet Neurol."},{"key":"156_CR189","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","volume":"71","author":"S Manzi","year":"2012","unstructured":"Manzi, S. et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann. Rheum. Dis. 71, 1833\u20131838 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"156_CR190","unstructured":"Hanly, J. G. in Systemic Lupus Erythematosus 5th edn (ed. Lahita, R. G.) 727\u2013746 (Elsevier, 2005)."},{"key":"156_CR191","doi-asserted-by":"crossref","unstructured":"Erkan, D., Salmon, J. & Lockshin, M. in Kelley and Firestein\u2019s Textbook of Rheumatology (ed. Firestein, G. S.) 1389\u20131399 (Elsevier, 2017).","DOI":"10.1016\/B978-0-323-31696-5.00082-6"},{"key":"156_CR192","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","volume":"44","author":"PL Meroni","year":"2001","unstructured":"Meroni, P. L. et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-\u03b22-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 44, 2870\u20132878 (2001).","journal-title":"Arthritis Rheum."},{"key":"156_CR193","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","volume":"62","author":"H Jung","year":"2010","unstructured":"Jung, H. et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62, 863\u2013868 (2010).","journal-title":"Arthritis Rheum."},{"key":"156_CR194","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0961203312436866","volume":"21","author":"RCAPSRegistry Cervera","year":"2012","unstructured":"Cervera, R. CAPS Registry. Lupus 21, 755\u2013757 (2012).","journal-title":"Lupus"},{"key":"156_CR195","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie, R. et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376\u2013386 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"156_CR196","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","volume":"18","author":"V Chitu","year":"2006","unstructured":"Chitu, V. & Stanley, E. R. Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol. 18, 39\u201348 (2006).","journal-title":"Curr. Opin. Immunol."},{"key":"156_CR197","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clim.2016.08.019","volume":"185","author":"SA Chalmers","year":"2017","unstructured":"Chalmers, S. A. et al. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus. Clin. Immunol. 185, 100\u2013108 (2017).","journal-title":"Clin. Immunol."},{"key":"156_CR198","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nchembio.502","volume":"7","author":"RW Hendriks","year":"2011","unstructured":"Hendriks, R. W. Drug discovery: new Btk inhibitor holds promise. Nat. Chem. Biol. 7, 4\u20135 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"156_CR199","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4049\/jimmunol.181.1.288","volume":"181","author":"J Jongstra-Bilen","year":"2008","unstructured":"Jongstra-Bilen, J. et al. Dual functions of Bruton\u2019s tyrosine kinase and Tec kinase during Fc\u03b3 receptor-induced signaling and phagocytosis. J. Immunol. 181, 288\u2013298 (2008).","journal-title":"J. Immunol."},{"key":"156_CR200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085834","volume":"9","author":"J Ni Gabhann","year":"2014","unstructured":"Ni Gabhann, J. et al. Btk regulates macrophage polarization in response to lipopolysaccharide. PLOS ONE 9, e85834 (2014).","journal-title":"PLOS ONE"},{"key":"156_CR201","doi-asserted-by":"crossref","DOI":"10.1038\/srep26164","volume":"6","author":"SA Chalmers","year":"2016","unstructured":"Chalmers, S. A. et al. Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton\u2019s tyrosine kinase. Sci. Rep. 6, 26164 (2016).","journal-title":"Sci. Rep."},{"key":"156_CR202","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.38047","volume":"65","author":"P Mina-Osorio","year":"2013","unstructured":"Mina-Osorio, P. et al. Suppression of glomerulonephritis in lupus-prone NZB \u00d7 NZW mice by RN486, a selective inhibitor of Bruton\u2019s tyrosine kinase. Arthritis Rheum. 65, 2380\u20132391 (2013).","journal-title":"Arthritis Rheum."},{"key":"156_CR203","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.4049\/jimmunol.1301553","volume":"191","author":"AL Rankin","year":"2013","unstructured":"Rankin, A. L. et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J. Immunol. 191, 4540\u20134550 (2013).","journal-title":"J. Immunol."},{"key":"156_CR204","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32\u201342 (2013).","journal-title":"N. Engl. J. Med."},{"key":"156_CR205","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.autrev.2014.04.002","volume":"13","author":"EM Zardi","year":"2014","unstructured":"Zardi, E. M., Taccone, A., Marigliano, B., Margiotta, D. P. & Afeltra, A. Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. Autoimmun. Rev. 13, 831\u2013839 (2014).","journal-title":"Autoimmun. Rev."},{"key":"156_CR206","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0269-8","volume":"13","author":"S Kivity","year":"2015","unstructured":"Kivity, S., Agmon-Levin, N., Zandman-Goddard, G., Chapman, J. & Shoenfeld, Y. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 13, 43 (2015).","journal-title":"BMC Med."},{"key":"156_CR207","volume":"17","author":"L Zhang","year":"2017","unstructured":"Zhang, L., Fu, T., Yin, R., Zhang, Q. & Shen, B. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry 17, 70 (2017).","journal-title":"BMC Psychiatry"},{"key":"156_CR208","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1546-0096-11-36","volume":"11","author":"S Torreggiani","year":"2013","unstructured":"Torreggiani, S. et al. Chorea, a little-known manifestation in systemic lupus erythematosus: short literature review and four case reports. Pediatr. Rheumatol. 11, 36 (2013).","journal-title":"Pediatr. Rheumatol."},{"key":"156_CR209","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jocn.2017.06.003","volume":"44","author":"XY Li","year":"2017","unstructured":"Li, X. Y., Xiao, H. B. & Pai, P. Myelitis in systemic lupus erythematosus. J. Clin. Neurosci. 44, 18\u201322 (2017).","journal-title":"J. Clin. Neurosci."},{"key":"156_CR210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.autrev.2017.01.011","volume":"16","author":"M Piga","year":"2017","unstructured":"Piga, M. et al. Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun. Rev. 16, 244\u2013252 (2017).","journal-title":"Autoimmun. Rev."},{"key":"156_CR211","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/art.22451","volume":"56","author":"H Fragoso-Loyo","year":"2007","unstructured":"Fragoso-Loyo, H. et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 56, 1242\u20131250 (2007).","journal-title":"Arthritis Rheum."},{"key":"156_CR212","first-page":"485","volume":"30","author":"R Dellalibera-Joviliano","year":"2003","unstructured":"Dellalibera-Joviliano, R., Dos Reis, M. L., Cunha Fde, Q. & Donadi, E. A. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J. Rheumatol. 30, 485\u2013492 (2003).","journal-title":"J. Rheumatol."},{"key":"156_CR213","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1351-5101.2003.00706.x","volume":"11","author":"K Baraczka","year":"2004","unstructured":"Baraczka, K., Nekam, K., Pozsonyi, T., Szuts, I. & Ormos, G. Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur. J. Neurol. 11, 37\u201342 (2004).","journal-title":"Eur. J. Neurol."},{"key":"156_CR214","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1590\/abd1806-4841.20153893","volume":"90","author":"MV Quaresma","year":"2015","unstructured":"Quaresma, M. V. et al. Anti-TNF-\u03b1 and hydralazine drug-induced lupus. An. Bras. Dermatol. 90, 125\u2013129 (2015).","journal-title":"An. Bras. Dermatol."},{"key":"156_CR215","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1084\/jem.20062567","volume":"204","author":"JR Groom","year":"2007","unstructured":"Groom, J. R. et al. BAFF and MyD88 signals promote a lupus like disease independent of T cells. J. Exp. Med. 204, 1959\u20131971 (2007).","journal-title":"J. Exp. Med."},{"key":"156_CR216","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","volume":"166","author":"J Zhang","year":"2001","unstructured":"Zhang, J. et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166, 6\u201310 (2001).","journal-title":"J. Immunol."},{"key":"156_CR217","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow, M. K. Type I interferon in the pathogenesis of lupus. J. Immunol. 192, 5459\u20135468 (2014).","journal-title":"J. Immunol."},{"key":"156_CR218","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.coi.2004.09.014","volume":"16","author":"EC Baechler","year":"2004","unstructured":"Baechler, E. C., Gregersen, P. K. & Behrens, T. W. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801\u2013807 (2004).","journal-title":"Curr. Opin. Immunol."},{"key":"156_CR219","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1461145702003103","volume":"5","author":"M Wichers","year":"2002","unstructured":"Wichers, M. & Maes, M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 5, 375\u2013388 (2002).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"156_CR220","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fimmu.2013.00484","volume":"4","author":"AD Stock","year":"2013","unstructured":"Stock, A. D., Wen, J. & Putterman, C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK\/Fn14 pathway. Front. Immunol. 4, 484 (2013).","journal-title":"Front. Immunol."},{"key":"156_CR221","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nrrheum.2010.64","volume":"6","author":"L Ronnblom","year":"2010","unstructured":"Ronnblom, L. & Elkon, K. B. Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 339\u2013347 (2010).","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0156-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:15:09Z","timestamp":1694553309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-018-0156-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":221,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1038\/s41584-018-0156-8","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"18 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.P. declares that he has received research funding from Biogen Idec for studies of the TNF-like weak inducer of apoptosis (TWEAK) pathway and from Boehringer Ingelheim for studies of tyrosine-protein kinase BTK inhibition in animal models of lupus. N.S. and A.D.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}